Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
Summary
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking...
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
Tags
JNJ
Related Articles
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
JNJ
PositiveBoston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case
JNJ
NeutralJohnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
JNJ
Positive